
Transdermal Drug Delivery System Industry Research Report 2024
Description
Transdermal Drug Delivery System Industry Research Report 2024
Summary
Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.
According to APO Research, The global Transdermal Drug Delivery System market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Transdermal Drug Delivery System is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Transdermal Drug Delivery System is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Transdermal Drug Delivery System is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Transdermal Drug Delivery System include Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), Johnson & Johnson, Lohmann, Teikoku Seiyaku and Bayer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Transdermal Drug Delivery System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transdermal Drug Delivery System.The Transdermal Drug Delivery System market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Transdermal Drug Delivery System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
HisamitsuMylanGSKNovartisTeve (Actavis)Johnson & JohnsonLohmannTeikoku SeiyakuBayerLingruiSanofiQizhengEndoHuarun 999Haw ParNichibanMentholatumLaboratoires GenevrierTransdermal Drug Delivery System segment by Type
FentanylNitroglycerinEstradiolNicotineOtherTransdermal Drug Delivery System Segment by Application
OTCRxTransdermal Drug Delivery System Segment by Region
North AmericaUnited StatesCanadaEuropeGermanyFranceUKItalyRussiaNordic CountriesRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of AsiaLatin AmericaMexicoBrazilRest of Latin AmericaMiddle East & AfricaTurkeySaudi ArabiaUAERest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transdermal Drug Delivery System market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transdermal Drug Delivery System and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transdermal Drug Delivery System.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Transdermal Drug Delivery System companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
128 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Transdermal Drug Delivery System by Type
- 2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
- 2.2.2 Fentanyl
- 2.2.3 Nitroglycerin
- 2.2.4 Estradiol
- 2.2.5 Nicotine
- 2.2.6 Other
- 2.3 Transdermal Drug Delivery System by Application
- 2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
- 2.3.2 OTC
- 2.3.3 Rx
- 2.4 Assumptions and Limitations
- 3 Transdermal Drug Delivery System Breakdown Data by Type
- 3.1 Global Transdermal Drug Delivery System Historic Market Size by Type (2019-2024)
- 3.2 Global Transdermal Drug Delivery System Forecasted Market Size by Type (2025-2030)
- 4 Transdermal Drug Delivery System Breakdown Data by Application
- 4.1 Global Transdermal Drug Delivery System Historic Market Size by Application (2019-2024)
- 4.2 Global Transdermal Drug Delivery System Forecasted Market Size by Application (2019-2024)
- 5 Global Growth Trends
- 5.1 Global Transdermal Drug Delivery System Market Perspective (2019-2030)
- 5.2 Global Transdermal Drug Delivery System Growth Trends by Region
- 5.2.1 Global Transdermal Drug Delivery System Market Size by Region: 2019 VS 2023 VS 2030
- 5.2.2 Transdermal Drug Delivery System Historic Market Size by Region (2019-2024)
- 5.2.3 Transdermal Drug Delivery System Forecasted Market Size by Region (2025-2030)
- 5.3 Transdermal Drug Delivery System Market Dynamics
- 5.3.1 Transdermal Drug Delivery System Industry Trends
- 5.3.2 Transdermal Drug Delivery System Market Drivers
- 5.3.3 Transdermal Drug Delivery System Market Challenges
- 5.3.4 Transdermal Drug Delivery System Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Transdermal Drug Delivery System Players by Revenue
- 6.1.1 Global Top Transdermal Drug Delivery System Players by Revenue (2019-2024)
- 6.1.2 Global Transdermal Drug Delivery System Revenue Market Share by Players (2019-2024)
- 6.2 Global Transdermal Drug Delivery System Industry Players Ranking, 2022 VS 2023 VS 2024
- 6.3 Global Key Players of Transdermal Drug Delivery System Head office and Area Served
- 6.4 Global Transdermal Drug Delivery System Players, Product Type & Application
- 6.5 Global Transdermal Drug Delivery System Players, Date of Enter into This Industry
- 6.6 Global Transdermal Drug Delivery System Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Transdermal Drug Delivery System Market Size (2019-2030)
- 7.2 North America Transdermal Drug Delivery System Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 7.3 North America Transdermal Drug Delivery System Market Size by Country (2019-2024)
- 7.4 North America Transdermal Drug Delivery System Market Size by Country (2025-2030)
- 7.5 United States
- 7.6 Canada
- 8 Europe
- 8.1 Europe Transdermal Drug Delivery System Market Size (2019-2030)
- 8.2 Europe Transdermal Drug Delivery System Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 8.3 Europe Transdermal Drug Delivery System Market Size by Country (2019-2024)
- 8.4 Europe Transdermal Drug Delivery System Market Size by Country (2025-2030)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Russia
- 8.10 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Transdermal Drug Delivery System Market Size (2019-2030)
- 9.2 Asia-Pacific Transdermal Drug Delivery System Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 9.3 Asia-Pacific Transdermal Drug Delivery System Market Size by Country (2019-2024)
- 9.4 Asia-Pacific Transdermal Drug Delivery System Market Size by Country (2025-2030)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 Southeast Asia
- 9.9 India
- 9.10 Australia
- 10 Latin America
- 10.1 Latin America Transdermal Drug Delivery System Market Size (2019-2030)
- 10.2 Latin America Transdermal Drug Delivery System Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 10.3 Latin America Transdermal Drug Delivery System Market Size by Country (2019-2024)
- 10.4 Latin America Transdermal Drug Delivery System Market Size by Country (2025-2030)
- 10.5 Mexico
- 10.6 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Transdermal Drug Delivery System Market Size (2019-2030)
- 11.2 Middle East & Africa Transdermal Drug Delivery System Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 11.3 Middle East & Africa Transdermal Drug Delivery System Market Size by Country (2019-2024)
- 11.4 Middle East & Africa Transdermal Drug Delivery System Market Size by Country (2025-2030)
- 11.5 Turkey
- 11.6 Saudi Arabia
- 11.7 UAE
- 12 Players Profiled
- 12.1 Hisamitsu
- 12.1.1 Hisamitsu Company Information
- 12.1.2 Hisamitsu Business Overview
- 12.1.3 Hisamitsu Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.1.4 Hisamitsu Transdermal Drug Delivery System Product Portfolio
- 12.1.5 Hisamitsu Recent Developments
- 12.2 Mylan
- 12.2.1 Mylan Company Information
- 12.2.2 Mylan Business Overview
- 12.2.3 Mylan Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.2.4 Mylan Transdermal Drug Delivery System Product Portfolio
- 12.2.5 Mylan Recent Developments
- 12.3 GSK
- 12.3.1 GSK Company Information
- 12.3.2 GSK Business Overview
- 12.3.3 GSK Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.3.4 GSK Transdermal Drug Delivery System Product Portfolio
- 12.3.5 GSK Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.4.4 Novartis Transdermal Drug Delivery System Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Teve (Actavis)
- 12.5.1 Teve (Actavis) Company Information
- 12.5.2 Teve (Actavis) Business Overview
- 12.5.3 Teve (Actavis) Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.5.4 Teve (Actavis) Transdermal Drug Delivery System Product Portfolio
- 12.5.5 Teve (Actavis) Recent Developments
- 12.6 Johnson & Johnson
- 12.6.1 Johnson & Johnson Company Information
- 12.6.2 Johnson & Johnson Business Overview
- 12.6.3 Johnson & Johnson Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.6.4 Johnson & Johnson Transdermal Drug Delivery System Product Portfolio
- 12.6.5 Johnson & Johnson Recent Developments
- 12.7 Lohmann
- 12.7.1 Lohmann Company Information
- 12.7.2 Lohmann Business Overview
- 12.7.3 Lohmann Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.7.4 Lohmann Transdermal Drug Delivery System Product Portfolio
- 12.7.5 Lohmann Recent Developments
- 12.8 Teikoku Seiyaku
- 12.8.1 Teikoku Seiyaku Company Information
- 12.8.2 Teikoku Seiyaku Business Overview
- 12.8.3 Teikoku Seiyaku Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.8.4 Teikoku Seiyaku Transdermal Drug Delivery System Product Portfolio
- 12.8.5 Teikoku Seiyaku Recent Developments
- 12.9 Bayer
- 12.9.1 Bayer Company Information
- 12.9.2 Bayer Business Overview
- 12.9.3 Bayer Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.9.4 Bayer Transdermal Drug Delivery System Product Portfolio
- 12.9.5 Bayer Recent Developments
- 12.10 Lingrui
- 12.10.1 Lingrui Company Information
- 12.10.2 Lingrui Business Overview
- 12.10.3 Lingrui Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.10.4 Lingrui Transdermal Drug Delivery System Product Portfolio
- 12.10.5 Lingrui Recent Developments
- 12.11 Sanofi
- 12.11.1 Sanofi Company Information
- 12.11.2 Sanofi Business Overview
- 12.11.3 Sanofi Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.11.4 Sanofi Transdermal Drug Delivery System Product Portfolio
- 12.11.5 Sanofi Recent Developments
- 12.12 Qizheng
- 12.12.1 Qizheng Company Information
- 12.12.2 Qizheng Business Overview
- 12.12.3 Qizheng Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.12.4 Qizheng Transdermal Drug Delivery System Product Portfolio
- 12.12.5 Qizheng Recent Developments
- 12.13 Endo
- 12.13.1 Endo Company Information
- 12.13.2 Endo Business Overview
- 12.13.3 Endo Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.13.4 Endo Transdermal Drug Delivery System Product Portfolio
- 12.13.5 Endo Recent Developments
- 12.14 Huarun 999
- 12.14.1 Huarun 999 Company Information
- 12.14.2 Huarun 999 Business Overview
- 12.14.3 Huarun 999 Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.14.4 Huarun 999 Transdermal Drug Delivery System Product Portfolio
- 12.14.5 Huarun 999 Recent Developments
- 12.15 Haw Par
- 12.15.1 Haw Par Company Information
- 12.15.2 Haw Par Business Overview
- 12.15.3 Haw Par Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.15.4 Haw Par Transdermal Drug Delivery System Product Portfolio
- 12.15.5 Haw Par Recent Developments
- 12.16 Nichiban
- 12.16.1 Nichiban Company Information
- 12.16.2 Nichiban Business Overview
- 12.16.3 Nichiban Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.16.4 Nichiban Transdermal Drug Delivery System Product Portfolio
- 12.16.5 Nichiban Recent Developments
- 12.17 Mentholatum
- 12.17.1 Mentholatum Company Information
- 12.17.2 Mentholatum Business Overview
- 12.17.3 Mentholatum Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.17.4 Mentholatum Transdermal Drug Delivery System Product Portfolio
- 12.17.5 Mentholatum Recent Developments
- 12.18 Laboratoires Genevrier
- 12.18.1 Laboratoires Genevrier Company Information
- 12.18.2 Laboratoires Genevrier Business Overview
- 12.18.3 Laboratoires Genevrier Revenue in Transdermal Drug Delivery System Business (2019-2024)
- 12.18.4 Laboratoires Genevrier Transdermal Drug Delivery System Product Portfolio
- 12.18.5 Laboratoires Genevrier Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.